New hope for tough anemia: drug boosts blood cells in failed cases
NCT ID NCT03988608
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called eltrombopag in 20 Chinese adults with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. Participants had not responded to previous treatments. The drug was given daily for up to a year to see if it could improve blood cell counts and reduce the need for transfusions. The goal was to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nanjing, Jiangsu, 210000, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Tianjin, 300052, China